相关实验视频
Updated: Jun 18, 2025

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
黑人参:一种用于治疗心力衰竭的新药
Peiyuan Dou1, Linlin Liu2, Mozhu Jin2
1State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Frontiers in pharmacology
|August 2, 2024
概括
黑人参 (BG) 通过调节下丘脑-垂体轴和肠道微生物群,有效治疗心力衰竭 (HF). 它的成分,特别是总沙素分数 (TSF) 和多糖分数 (PSF),显示出显著的治疗潜力.
科学领域:
- 药理学和中国传统医学
- 心血管研究研究心血管研究
- 微生物组和代谢学
背景情况:
- 经过反复蒸和干燥加工的黑人人参 (BG) 含有罕见的香和二次人参化物.
- 红人参 (RG) 已知用于心力衰竭 (HF) 治疗,但由于稀有人参的含量更高,BG可能具有更高的疗效.
- 研究BG在HF治疗中的活性成分和机制对于了解其治疗潜力至关重要.
研究的目的:
- 为了研究黑人参 (BG) 和其分离物的对大鼠中异二醇 (ISO) 诱导的心力衰竭 (HF) 的影响.
- 阐明BG在HF治疗中的活性物质和潜在机制.
- 分析BG对内分泌轴,肠道微生物群和代谢概况的影响.
主要方法:
- 患有ISO诱导的HF的老鼠被用BG及其分量 (WEF,TSF,AEF) 治疗.
- 从下丘脑-垂体-上腺 (HPA) 和淋巴腺 (HPG) 轴的类固醇被使用UPLC-QqQ-MS/MS.量化.
- 分析了肠道微生物群 (16S rDNA测序),短链脂肪酸 (GC-MS),能量代谢和血清循环核酸 (ELISA).
主要成果:
- BG成分显著影响了下丘脑-垂体-甲状腺 (HPT) 和HPA轴.
- 低剂量的总沙素分离物 (TSFL),水分离物 (WD) 和高剂量的多糖分离物 (PSFH) 根据BNP,CK和E2/T水平显示出更高的疗效.
- BG成分,特别是WD和TSFL,调节了雄激素 (T,A4) 并通过肠道微生物群 (乳酸菌/烯酸) 和SCFA (乙酸盐,丁酸盐) 发挥了抗炎作用.
结论:
- 黑人参 (BG) 和其分离物 (TSF,PSF) 在缓解心力衰竭方面表现出显著的疗效.
- 在TSF中的关键活性成分包括人参化物Rk1,Rk3,20-(S) -Rg3和20-(S) -Rh2.
- BG的治疗作用包括对雄激素激素的调节,eNOS-NO通路和来自肠道微生物群的抗炎机制.
相关概念视频
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Antianginal Drugs: Nitrates and β-Blockers
564
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
564
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K

